Shares of Neogen Corporation (NASDAQ:NEOG – Get Free Report) have been given a consensus rating of “Hold” by the five ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $12.00.
A number of equities research analysts have commented on the company. Wall Street Zen upgraded Neogen from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings raised shares of Neogen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Finally, Piper Sandler upgraded shares of Neogen from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $13.00 to $14.00 in a report on Wednesday.
Get Our Latest Analysis on Neogen
Key Headlines Impacting Neogen
- Positive Sentiment: Piper Sandler upgraded Neogen on new management. The brokerage’s improved view suggests investors may expect management changes to improve execution, profitability, or growth. Neogen upgraded at Piper Sandler on new management
- Positive Sentiment: Zacks Research raised several future EPS forecasts. Estimates increased for the second and third quarters of fiscal 2027, the fourth quarter of fiscal 2027, and the third and fourth quarters of fiscal 2028. The full-year fiscal 2028 forecast also rose to $0.29 per share from $0.28, indicating modestly better expected earnings momentum. The current-year consensus remains $0.25 per share.
- Positive Sentiment: Neogen is receiving attention from value-oriented investors. A Zacks comparison of Neogen and Perrigo highlights investor interest in the medical-products sector and could increase visibility for NEOG among investors seeking a relatively attractive valuation. PRGO or NEOG: Which Is the Better Value Stock Right Now?
- Neutral Sentiment: Analysts’ price target is near the recent trading level. The reported consensus target of $11.67 suggests limited near-term upside based on that estimate, although targets can change following the Piper Sandler upgrade. Analysts Set Neogen Corporation PT at $11.67
- Neutral Sentiment: Short-interest data provides no meaningful signal. The report lists zero shares sold short and a zero-day short ratio, figures that appear anomalous and do not indicate either significant short-covering potential or notable bearish positioning.
- Negative Sentiment: Not all forecasts improved. Zacks lowered its fiscal first-quarter 2028 EPS estimate to $0.05 from $0.06, signaling that the earnings outlook remains uneven despite the broader upward revisions.
Institutional Investors Weigh In On Neogen
A number of institutional investors have recently modified their holdings of NEOG. Nykredit A S purchased a new position in shares of Neogen during the 2nd quarter valued at $28,000. Public Employees Retirement System of Ohio acquired a new position in shares of Neogen in the second quarter worth $34,000. UMB Bank n.a. increased its stake in shares of Neogen by 238.2% in the fourth quarter. UMB Bank n.a. now owns 6,422 shares of the company’s stock worth $45,000 after acquiring an additional 4,523 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Neogen by 816.9% during the fourth quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company’s stock worth $53,000 after acquiring an additional 6,764 shares in the last quarter. Finally, Cresset Asset Management LLC purchased a new stake in shares of Neogen during the second quarter worth $53,000. Institutional investors and hedge funds own 96.73% of the company’s stock.
Neogen Price Performance
Shares of NASDAQ:NEOG opened at $11.70 on Thursday. The company’s fifty day moving average is $10.37 and its two-hundred day moving average is $9.85. The company has a market cap of $2.55 billion, a P/E ratio of -390.00, a price-to-earnings-growth ratio of 4.59 and a beta of 1.77. Neogen has a 12-month low of $4.90 and a 12-month high of $12.85. The company has a quick ratio of 2.91, a current ratio of 3.82 and a debt-to-equity ratio of 0.38.
Neogen (NASDAQ:NEOG – Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.06 by $0.03. Neogen had a positive return on equity of 2.78% and a negative net margin of 0.91%.The business had revenue of $225.30 million during the quarter, compared to analysts’ expectations of $212.35 million. During the same quarter last year, the firm posted ($2.82) earnings per share. Neogen’s revenue was down .1% compared to the same quarter last year. Equities analysts expect that Neogen will post 0.25 earnings per share for the current fiscal year.
Neogen Company Profile
Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.
In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.
Featured Stories
- Five stocks we like better than Neogen
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.
